Almirall 1st semester: excellent news in r & d and confirmed forecasts.
Almirall 1st semester: excellent news in r & d and confirmed forecasts. – are confirmed annual financial estimates -Solid balance sheet and good free cash flow generation -aclidinio monotherapy has been approved in Europe and United States -the linaclotida in Europe for regulatory process runs its course -new subsidiary in Canada Barcelona, August 2012.- Almirall international pharmaceutical company headquartered in Barcelona, has announced its results for the first half 2012. financial data highlights (rounded million €) Eduardo Sanchiz, Consejero Delegado, comenta: “We are very happy and proud of how the monotherapy aclidinio regulatory process has gone on both sides of the Atlantic. The result speaks very well of the work and the strength of the information submitted to the authorities. In parallel, we are undertaking important work to prepare us for the new releases. We have established business partnerships that can provide a competitive position for our product in 80% of the world market of COPD, while we reinforce our market access and trade organizations. In addition, the regulatory linaclotida in Europe for process runs its course and response we expect in the coming months. “In summary, despite the difficulties in our domestic market, we reiterate our forecasts for 2012 and we are ready to start a period which could lead to a significant transformation of our business in the coming years”. Approval of aclidinio and confirmation of forecasts...
Read More